Prescient Therapeutics: Advancing cancer treatment with PTX-100 and cell therapies
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is aiming to establish new frontiers in cancer care, with...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is aiming to establish new frontiers in cancer care, with...
Prescient Therapeutics (ASX: PTX) earlier this week began its Phase 2A clinical trial of PTX-100...
Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the initiation of a Phase...
Prescient Therapeutics Ltd has kicked off its Phase 2a clinical trial evaluating PTX-100 for relapsed...
Prescient Therapeutics Ltd has received Fast Track Designation from the United States Food and Drug...
Prescient Therapeutics Ltd has appointed Melanie Farris as an independent non-executive director, further strengthening its...
Clinical-stage oncology company Prescient Therapeutics Ltd has opened the first clinical site for its Phase...
Prescient Therapeutics Ltd has appointed Dr Marissa Lim as Chief Medical Officer, effective March 24,...
Prescient Therapeutics Ltd is set to present data from its Phase 1b study of PTX-100...
With new CEO James McDonnell in place and FDA clearance for its Investigational New Drug application, 2025...
This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.